Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis

Annals of Internal Medicine

Volumn 134, Issue 2, 2001, Pages 89-95

  Tung, B Y ^a   Emond, M J ^a   Haggitt, R C ^a   Bronner, M P ^a   Kimmey, M B ^a   Kowdley, K V ^a   Brentnall, T A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MESALAZINE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; URSODEOXYCHOLIC ACID;

ADULT; ARTICLE; CANCER PREVENTION; COLON CANCER; COLON TUMOR; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DYSPLASIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PREVALENCE; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; RISK FACTOR; ULCERATIVE COLITIS;

EID: 0035895263     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-134-2-200101160-00008     Document Type: Article

References (44)

1. Ulcerative colitis and colorectal cancer. A population-based study
2. Colorectal cancer in ulcerative colitis. Influence of anatomical extent and age at onset on colitis-cancer interval
3. Liver disease in ulcerative colitis: An epidemiological and follow up study in the county of Stockholm
4. Prevalence of primary sclerosing cholangitis in patients with ulcerative colitis
5. Relationship of inflammatory bowel disease and primary sclerosing cholangitis
6. Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis
7. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis
8. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential
9. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis
10. Colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis
11. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study
12. Relation of meat, fat, and fiber intake to the risk of colon cancer in a prospective study among women
13. Dietary fat and its relationship to large bowel cancer
14. Increased serum deoxycholic acid levels in men with colorectal adenomas
15. Aspirin use and reduced risk of fatal colon cancer
16. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
17. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma
18. Risk factors for colorectal cancer in patients with ulcerative colitis: A case-control study
19. Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: A retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire
20. Ursodiol for primary sclerosing cholangitis
21. The site-specific delivery of ursodeoxycholic acid to the rat colon by sulfate conjugation
22. Prevention of N-methyl-nitrosourea-induced colon tumorigenesis by ursodeoxycholic acid in F344 rats
23. Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid
24. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications
25. Faecal bile acids, dysplasia, and carcinoma in ulcerative colitis
26. Proliferative activity of rectal mucosa and soluble fecal bile acids in patients with normal colons and in patients with colonic polyps or cancer
27. Metabolic epidemiology of colon cancer. Fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps
28. Colonic mucosal proliferation is related to serum deoxycholic acid levels
29. Different bile acids exhibit distinct biological effects: The tumor promoter deoxycholic acid induces apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell proliferation
30. Effects of dietary bile acids on formation of azoxymethane-induced aberrant crypt foci in F344 rats
31. Effect of cholic acid feeding on N-methyl-N-nitrosourea-induced colon tumors and cell kinetics in rats
32. Effects of calcium and bile acid feeding on colon tumors in the rat
33. Experimental colorectal cancer: The relationship of diet and faecal bile acid concentration to tumour induction
34. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps
35. Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids
36. Mechanism of action of chemoprotective ursodeoxycholate in the azoxymethane model of rat colonic carcinogenesis: Potential roles of protein kinase C-alpha, -beta II, and -zeta
37. The chemopreventive role of ursodeoxycholic acid in azoxymethane-treated rats: Suppressive effects on enhanced group II phospholipase A2 expression in colonic tissue
38. Altered protein kinase C activity in biopsies of human colonic adenomas and carcinomas
39. Protein kinase C activity in human colonic adenoma and colorectal carcinoma
40. Studies on protein kinase C and colon carcinogenesis
41. Protein kinase C activity of colonic mucosa in ulcerative colitis
42. Activities of phospholipase A2 and diacylglycerol lipase are increased in human colorectal cancer
43. Increased group II phospholipase A2 in colonic mucosa of patients with Crohn's disease and ulcerative colitis
44. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants